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Sary Interferon (IFN-a) enhances the activity of 5-fluorouracil (5-FU) in the treatment of advanced
colorectal cancer although the mechanism is not understood. We have investigated the effect of this combina-
tion on cellular immunity and compared this with standard therapy of 5-FU/L-leucovorin, in 24 patients with
advanced colorectal cancer. This study has demonstrated an enhancement of the cellular immune response m
patients given 5-FU/IFN-a with augmentation of natural killer (NK) cel function and abrogation of
5-FU-induced suppression of lymphokine-activated killer (LAK) cell activity.
The combination of 5-fluorouracil (5-FU) and alpha
interferon (IFN-a) is used increasingly in the treatment of
advanced colorectal cancer. The initial phase II trial using
this combination achieved objective responses in 60% of
patients (Wadler et al., 1989) and, although a large phase Ill
study failed to demonstrate such impressive results (Kocha,
1993), they were, nevertheless similar to results with 5-FU
and L-leucovorin. 5-FU and L-leucovorin is considered the
standard treatment for advanced colorectal cancer, having
achieved partial response rates in approximately 40% of
patients with modest survival benefit (Petrelli et al., 1989;
Poon et al., 1989).
The mechanism by which IFN-a modulates the activity of
5-FU is unknown. In vitro cytoxicity studies using gastro-
intestinal cell lines how that interferon acts synergistically
with 5-FU (Wadler et al., 1990). It may be acting as an
antiproliferative agent, either by biochemically modulating
the effect of 5-FU or by some other mechanism. While other
reports suggest that interferon alters the pharmacokinetics of
5-FU (Grem et al., 1991; Schuller et al., 1992) we have
demonstrated that the steady-state plasma levels of 5-FU
during two 5-day infusions, with and without IFN-a in the
same patients, showed no significant differences (Pitman et
al., 1993).
Another possibility is that IFN-a may be acting through
an immunological mechanism. It is known to augment
natural killer (NK) cell activity, and it up-regulates expres-
sion of both class I MHC antigen and tumour-associated
antigen in tumours (Trincheri et al., 1985), perhaps with the
effect of making the tumour more immunogenic. However,
little is known about the immunological effects of 5-FU when
combined with IFN-a. We have, therefore, studied the effects
of this combination on several aspects of cellular immune
function in patients with advanced colorectal cancer. The
results are compared with those of a control group treated
with the conventional therapy of 5-FU and L-leucovorin.
Materials and methods
Patients
Twenty-four patients were studied, 15 male and nine female.
The mean ages were 58 (range 27-76) for the control group
and 60 (42-78) for those receiving 5-FU with IFN-a. All
patients had histologically proven metastatic colorectal
cancer, the sites of metastases being shown in Table I. The
time interval between presentation with the primary tumour
and recurrent disease averaged 16 (range 0-91 months).
Performance status was assessed by means of the Karnofsky
scale (Karnofsky et al., 1948), and averaged 80 with a range
of 70-90.
Written consent was obtained prior to study entry. The
study was approved by Leeds East District Clinical Research
(Ethics) Committee.
Treatment schedule
Patients were randomised independently of the authors to
receive either 5-FU/IFN-a or 5-FU/L-leucovorin. Fifteen
patients were treated with the 5-FU/IFN-a regimen as first
reported by Wadler et al. (1989). 5-FU was administered as a
continuous intravenous infusion for 5 days at a dose of
750mgm-2day-'. This was followed by a weekly bolus dose
of 750mgm2 commencing on day 15. Interferon alpha-2ax
9 MU (Roferon-A; Roche Products, Basle, Switzerland) was
administered as a subcutaneous injection three times weekly.
Nine patients received 5-FU and leucovorin. L-leucovonn,
200mgm2, was infused over 10 min and followed within
5 min by an intravenous bolus dose of 5-FU at 370 mgm-2
for five consecutive days. This cycle was repeated every 4
weeks (Erlichman et al., 1988). There were no differences
between the study and control groups in terms of age, sex,
burden or distribution of disease or performance status.
Twnour assessment
Serial computerised tomographic (CT) scanning was per-
formed within 2 weeks prior to starting treatment, and at 8
Table I The characteristics of the patients in both arms of the
study, the sites of metastasis and the response to treatment
5-FU + leucovorin 5-HI + IFN-z
n 9 15
Mean age (range) 60 (42-79) 58 (28-76)
Male:Female 5:4 10:5
Metastatic site:
Liver 3 8
Lung 1 1
Liver + lung 4 3
Peritoneal 1 3
Response to treatment:
Complete response 0 0
Partial response 1 6
Stable disease 3 4
Progressive disease 5 5
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weekly intervals thereafter to assess response. Tumour re-
sponse was graded in accordance with WHO criteria as
described in WHO (1979).
Immunological studies
Baseline assessment of lymphocyte number and function was
performed before and after the first week of treatment, and
subsequently at 4 weekly intervals prior to the next cycle of
chemotherapy. For each analysis, a sample of peripheral
venous blood was obtained between 08.30 h and 09.30 h to
minimise the influence of diurnal variation and the following
measurements performed.
Lymphocyte separation
Peripheral blood mononuclear cells (PBMCs) were separated
from heparinised blood by Lymphoprep (Nycomed Pharma,
Oslo, Norway) density-gradient centrifugation after the
method of Boyum (1968) and resuspended in complete
medium as previously described (Nichols et al., 1992). The
cells were counted in a Neubauer counting chamber and
diluted to the cell density required for each expeniment.
Cytotoxicity assay
A standard 4 h chromium-release assay was used to assess
cell cytotoxicity (Ortaldo et al., 1997). Freshly isolated
PBMCs were used for determination of NK-cell activity with
the cell line K562 as target. LAK cells were generated by the
co-culture of 15 x 106 fresh PBMCs with 1,000unitsml '
recombinant interleukin 2 (rIL-2) in 10 ml of complete
medium. Cells were incubated for 3 days at 37C in a
humidified atmosphere containing 5% carbon dioxide, prior
to use as effectors in the cytotoxicity assay. This was per-
formed in the same way as for the NK assay but using two
NK-resistant cell lines as targets, DAUDI (a reference target
for LAK cell activity) and COLO 205 (a colonic adenocar-
cinoma cell line). For details of experimental method see
Nichols et al. (1992).
To standardise cytolytic activity, results were derived from
the area under the curve (AUC) of the log(effector)/response
curve exactly as described by Dye et al. (1991).
Cell-surface markers
Enumeration of leucocyte subpopulations was performed by
flow cytometry using a panel of directly conjugated mono-
clonal antibodies directed against cell-surface antigens.
EDTA-stored blood was labelled using a whole-blood tech-
nique (Nichols et al., 1992). The following monoclonal
antibodies were obtained from Dako (High Wycombe, UK):
UCHT1 (CD3, total T cells), MT310 (CD4, helper/inducer T
cells), DK25 (CD8, cytotoxic T cells), ACT-1 (CD25, p55
subunit IL-2 receptor), UCHL1 (CD45RO, T-cell activation
marker) and mouse IgGI isotype controls. Anti-Leu-l ic
(CD16, NK cells) was obtained from Becton Dickinson
Immunocytometry Systems. All antibodies were directly con-
jugated with either fluorescein isothiocyanate (FITC) or
phycoerythrin (PE).
Cell preparations were analysed on a Becton Dickinson
FACScan analytical flow cytometer. Analysis was performed
using 'Lysis II' software (Becton Dickinson) and results
determined by four-quadrant analysis having gated for
>99% positive cells on isotype controls.
Total leucocyte counts and differential cell counts were
performed on a Technicon HI analyser in the pathology
department of St James's University Hospital.
Statistical analysis
Statistical analysis was performed in accordance with Mat-
thews et al. (1990). In brief, for all the variables of interest
individual curves were drawn to establish the pattern of the
response. This allowed the identification of a single summary
measure for each individual to be used in the analysis. Com-
parisons between these summary measures were then made
using a Student t-test. Results are expressed as mean ± s.e.m.
with a probability value of <0.05 regarded as statistically
significant.
Reslts
Patient outcome
Response to treatment is shown in Table I. There were no
complete responses in either group, and no statistically
significnt differences in the number of partial responders:
1/9 in the control group and 5/14 in the IFN-a-treated
group.
Treatment-related complications
Treatment was tolerated well in both treatment groups, with
no dose reduction or interruption in therapy necessary. All
patients who entered the study were evaluable.
Lymphocytefunction analysis
Figure 1 demonstrates the percentage change in NK-cel
function between the two treatment groups. NK-cell function
(arbitrary units) was significantly reduced in the control
group following the first week of chemotherapy from
151.7 ± 19.6 to 121.3 ± 16.7. The level of activity failed to
return to pretreatment values prior to the next cycle of
therapy (122.9 ± 17.9). Using the summary analysis de-
scribed, the depression in NK-cell activity was significant
(P<0.02). In contrast, in those patients receiving IFN-x with
5-FU, NK-cell activity was augmented, incrang con-
sistently from a baseline of 117.0 ± 12.9 to 123.7 ± 14.8 after
I week and to 183.0 ± 16.9 after 26-28 weeks (P<0.05).
There was a marked difference between the two groups over
the first 12 weeks of treatment (P<0.01). NK-cxll activity
was seen to vary in relation to patient outcome, as shown in
Figure 2.
The percentage change in LAK-cell generation against the
DAUDI target is shown in Figure 3. As with NK-ceUl
activity, LAK-cell function was reduced following treatment
with 5-FU an L-leucovorin, from a pretreatment value of
265.4 ± 18.8 to 170.1 ± 30.2. Again activity remained reduced
prior to the next treatment cycle, 201.4 ± 23.4, although in
the longer term LAK-cell activity did return to pretreatment
levels. The depression in the LAK-cell activity in the first 10
weeks of treatment was statistically significant (P<0.02). In
contrast, treatment with 5-FU and IFN-a resulted in no such
fall in LAK-cell generative capacity.
Lymphocytephenotypic analysis
We failed to show any changes in the phenotypic pattern of
peripheral blood lymphocytes throughout our monitoring
period for both groups of patients (results not shown).
Numbers of circulating lymphocytes were, however, reduced
in those patients receiving IFN-x but not L-leucovonn
(P<0.01) (Figure 4).
This study demonstrates that 5-FU combined with L-leuco-
vorin, the most widely used modulated 5-FU regimen, has a
predominantly immunosuppressive effect. Both NK- and
LAK-cell activity were diminished after the first cycle of
treatment and did not return to the baseline level before the
next cycle. The NK-cell activity remained suppressed com-
pared with that in the 5-FU/IFN-a-treated group for a pro-
longed period. By contrast, the interferon-treated group
showed no suppression of NK- or LAK-ell activity, and
NK-cell activity was augmented.948 P.H. NICHOLS et al.
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Fiwe I The percentage change in natural killer (NK) cell
activity in relation to treatment. Treatment with 5-FU/L-leuco-
vorin (0) resulted in depression of NK-cell activity compared
with baseine (P<0.02) and the 5-FU/IFN-a-treated group (0)
(P<0.01). 5-FU/IFN-x treatment also increased NK-cell activity
(P<0.05). The data shown are means ± s.e.m.
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Fugwe 2 The percentage change in natural killer (NK) cell
activity in all the patients in this study in relation to response to
chemotherapy. NK activity was depressed in patients with pro-
gressive disease (P<0.05). A, Partial response; 0, stable disease;
0, progressive disease.
The NK-cell activity appears to be diminished in patients
who develop progressive disease. This effect is predominantly
due to the maintenance or enhancement of NK-cell activity
in the group receiving 5-FU and IFN-m; the one responder in
the group given 5-FU with L-leucovorin demonstrated quite
marked depression of NK-cell activity. One possible explana-
tion for this observation is that NK-cell activity simply
reflects tumour burden. It is well known that patients with
colorectal cancer are immunosuppressed and that this sup-
pression is greater with a large tumour load (Monson et al.,
1986). Thus, as the disease progresses, it may be expected
that there is deterioration in parameters that reflect immune
function. Similarly, as a patient's tumour burden decreases it
could be that there is an improvement in NK-cell activity.
This possible explanation is made less likely in view of the
immunosuppression observed in the control group given 5-
FU/L-leucovorin, even in those who respond. Similarly, the
minor differences in the 5-FU schedules between the two
regimens also seem unlikely to explain the difference.
The findings of this study prompt us to consider whether
at least some of the activity of the combination of 5-FU and
IFN-a may have an immunological basis. Natural killer cells
belong to the null cell lineage of large granular lymphocytes,
and as yet their function is not fully understood. They have
been shown to kill cancer cells in vitro, and it is thought that
NK cells play a major role in the destruction of circulating
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Fugwe 3 The percentage change in lymphokine-activated killer
(LAK) cell activity in relation to treatment. LAK activity was
depressed over the first 10 weeks of treatment in patients treated
with 5-FU/L-leucovorin (P<0.02). *, 5-FU + IFN-E; 0, 5-
FIJ + L-leucovorin.
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Fuge 4 The total lymphocyte count in relation to treatment.
The difference between the groups is significant (P<0.01). *,
5-FU + IFN-; 0, 5-FU + L-leucovorin.
tumour cells in vivo. As such, their principal activity is
against tumours of haematological origin as there is little
evidence that they have significant activity against solid
organ malignancies (Goldstein et al., 1986). Similarly,
although LAK cells do have activity against solid tumours
and 5-FU/IFN-x maintains the host ability to generate LAK
cells during in vitro culture with IL-2, no endogenous LAK
activity was demonstrated.
Although NK and LAK cells are unlikely to be effectors of
anti-tumour activity, it is possible that the maintenance/
augmentation of null cell killing activity reflects other
favourable alterations in the host response to the tumour.
For instance, IFN-x is known to up-regulate MHC class I
and tumour-associated antigen expression, this may render
the tumour more immunogenic and thus more susceptible to
T-cell killing (Trincheri et al., 1985). It is widely accepted
that a lymphocytic infiltrate has favourable prognostic
significance in colorectal tumours, hence there is prima facie
evidence of a role for the immune system in the control of
this malignancy.
Treatment with 5-FU/IFN-a resulted in a relative lympho-
penia when compared with 5-FU/L-leucovonn. This is a
well-recognised effect of IFN-x and may be as a result of
lymphocyte sequestration in peripheral sites, including poten-
tially tumour tissue. Neither treatment had any effect on the
lymphocyte subset analysis at any point in the study. This is
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of particular interest with regard to the CD16 marker which
labels NK cells. The fact that this marker remained un-
changed indicates that any enhancement in NK-cell activity
seen in the patients given IFN-a is due to the enhancement of
the individual cells' killing ability rather than an expansion of
cell numbers.
These studies do not establish that the enhanced efficacy of
the 5-FU/IFN-a combination is an immunological one. Other
possible mechanisms, such as an antiproliferative effect of
IFN-a or the possibility that the cytokine may biochemically
modulate 5-FU, warrant consideration. However, this study
has established that some aspects of cellular immunity are
maintained or enhanced in patients treated with 5-FU/IFN-a,
in contrast to the control group. This may reflect a general
increase in immune competence in these patients. Histological
examination of 5-FU/IFN-a-treated metastases and the typ-
ing of any lymphocytic infiltrate may be required to investi-
gate this possibility further.
Refaces
BOYUM, A. (1968). Separation of leukocytes from blood and bone
marrow. Scand. J. Clin. Lab. Invest., 21 (Suppl. 97).
DYE, J.F., SOMERS, S.S. & GUILLOU, PJ. (1991). Simplified quantita-
tion of cytotoxicity by integration ofspecific lysis against effector
cell concentration at a constant target cell concentration and
measuring the area under the curve. J. Immunol. Methods, 138,
1-13.
ERLICHMAN, C., FINE. S., WONG, A. & ELHAKIM, T. (1988). A
randomised trial of fluorouracil and folinic acid in patients with
metastatic colorectal carcinoma. J. Clin. Oncol., 6, 469-475.
GOLDSTEIN, D. & LASZLO, J. (1986). Interferon therapy in cancer:
from imagination to interferon. Cancer Res., 46, 4315-4329.
GREM. J.L.. MCATEE, N. & MURPHY. R-F. (1991). A pilot study of
interferon alfa-2a in combination with fluorouracil plus high-dose
Leucovorin in metastatic gastrointestinal carcinoma. J. Clin.
Oncol., 9, 1811-1820.
KARNOFSKY. D.A.. ADELMANN. W.H., CRAVER, L.F. & BUR-
CHENAL. J.H. (1948). The use of nitrogen mustard in the pal-
liative treatment of carcinoma. Cancer, 1, 634-656.
KOCHA, W. on behalf of the Corfu-A Collaborative Group (1993).
5-Fluorouracil (5-FU) plus interferon alfa-2a (Roferon A) versus
5-fluorouracil plus leucovorin (LV) in metastatic colorectal cancer
- results of a multinational, multicentre phase III study. Proc.
ASCO, 12, 193.
MATHEWS, J.N.S.. ALTMAN, D.G., CAMPBELL, MJ. & ROYSTON, P.
(1990). Analysis of serial measurements in medical research. Br.
Med. J., 300, 230-235.
MONSON. J.R.T.. RAMSDEN. C. & GUILLOU. PJ. (1986). Dereased
Interleukin-2 production in patients with gastrointestinal cancer.
Br. J. Surg., 73, 483-486.
NICHOLS. P.H.. RAMSDEN. C.W.. WARD, U., SEDMAN, P.C. & PRIM-
ROSE, J.N. (1992). Peri-operative immunotherapy with recom-
binant interleukin-2 in patients undergoing surgery for colorectal
cancer. Cancer Res., 50, 5765-5769.
ORTALDO. JR.R BONNARD, G.D. & HERBERMAN, R.B. (1977). Cyto-
toxic reactivity of human lymphocytes cultured in vitro. J.
Immunol., 119, 1351-1355.
PETRELLI. N., DOUGLASS, H.O., HERRERA, L.. RUSSELL, D..
STABLEIN, D.M., BRUCKNER. H.W., MAYER. RJ., SCHINELLA.
R., GREEN, M.D., MUGGIA, F.M., MEGIBOW, A., GREENWALD.
ES., BUKOWSKI, R.M., HARRIS, J., LEVIN, B., GAYNOR. E.,
LOUTFI, A., KALSER, M.K., BARKIN, J.S., BENEDETTO. P.,
WOOLLEY, P.V., NAUTA, R., WEAVER, D.W. & LEICHMAN, L.P.
(1989). The modulation of fluorouracil with leucovorin in meta-
static colorectal carcinoma: a prospective randomised phase III
trial. J. Clin. Oncol., 7, 1419-1426.
PITMANN, K_, PERREN, T., WARD, U., PRIMROSE, J., SLEVIN. M..
PATEL, N. & SELBY, P. (1993). Phanmacokinetics of 5-fluorouracil
in colorectal cancer patients receiving interferon. Ann. Oncol., 4,
515-516.
POON, MA., O'CONNELL, MJ., MOERTEL, C.G., WIEAND, H.S., CUL-
LINAN, S.A., EVERSON, L.K_ KROOK, J.E., MAILLIARD, J.A.,
LAURIE, JA._ TSCHETITER, L.K. & WIESENENFELD, M. (1989).
Biochemical modulation of 5-fluorouracil: evidence of significant
improvement of survival and quality of life in patients with
advanced colorectal carcinoma. J. Clin. Oncol., 7, 1407-1418.
SCHULLER. J_ CZEJKA. MJ. & SCHERNTHANER, G. (1992).
Influence of interferon alfa-28 with or without folinic acid on
pharmacokinetics of fluorouracil. Semin. Oncol., 19(2) (Suppl. 3),
93-97.
TRINCHERI, G. & PERUSSIA, B. (1985). Immune interferon: a pleio-
tropic lymphokine with multiple effects. Immunol Today, 6,
131-136.
WADLER, S., SCHWARTZ, E-L., GOLDMAN. M., LYVER, A.. RADER,
M., ZIMMERMAN, M., ITRI, L., WEINBERG, V. & WIERNIC, P.H.
(1989). Fluorouracil and recombinant alpha-2c-Interferon: an
active reimen against advanced colorectal carcinoma. J. Clin.
Oncol., 7, 1769-1775.
WADLER, S., WERSTO. R.. WEINBERG. V.. THOMPSON, D. &
SCHWARTZ, E.L. (1990). Interaction of fluorouracil and
interferon in human colon cancer cell lines: cytotoxic and
cytokinetic effects. Cancer Res., 50, 5735-5739.
WHO (1979). Handbook for Reporting Results of Cancer Treatment.
World Health Organization: Geneva.